ALK-Abello A/S (ALK B.CO) stock: key figures, P/E, revenue and dividend
Health Care · Denmark · ISIN DK0061802139
ALK-Abello A/S financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 5.54 bn DKK | 6.31 bn DKK |
| Gross profit | 3.55 bn DKK | 4.23 bn DKK |
| Operating income | 1.10 bn DKK | 1.66 bn DKK |
| EBIT | 1.09 bn DKK | 1.65 bn DKK |
| Net income | 815.00 m DKK | 1.20 bn DKK |
| Diluted EPS – continuing operations | 3.68 DKK | 5.40 DKK |
Full history since 2004, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ALK-Abello A/S
ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria; and ALK 014, a biologic for food allergies. It also provides GRAZAX/GRASTEK, a tablet for grass pollen allergy; ACARIZAX, ODACTRA, and MITICURE/SENSIMUNE, which are tablets for house dust mite allergies; ITULAZAX/ITULATEK, a tablet for tree pollen allergy; RAGWITEK/RAGWIZAX, a tablet for ragweed pollen allergy; and CEDARCURE, a tablet for Japanese cedar pollen allergy. In addition, the company offers consumer healthcare solutions, such as klarify.me, a digital patient engagement platform to help people manage their allergies. Further, it provides allergen extracts for use in the diagnosis of specific allergies, such as skin prick and blood test; and emergency medicine treatment, such as adrenaline autoinjectors, an intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. for the development of GRAZAX and CEDARCURE; and Dr. Reddy's Laboratories for the development of Sensimune. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.
More stocks
- KRATOS DEFENSE & SECURITY SOLUTIONS, INC. (KTOS)
- BOK FINANCIAL CORP (BOKF)
- AECOM (ACM)
- St James's Place PLC (STJ.L)
- IDACORP INC (IDA)
- Descartes Systems Group Inc (DSG.TO)
- CARMAX INC (KMX)
- MonotaRO Co Ltd (3064.T)
- Aurubis (NDA.DE)
- Vicinity Centres (VCX.AX)
- Indoritel Makmur Internasional (DNET.JK)
- Cinda Securities Co. Ltd. A (601059.SS)
Not investment advice. All data without warranty, price as of 16.10.2026. Details in the risk notice.